Canine symmetric dimethylarginine (cSDMA) Test Kit

cSDMA originates from the intranuclear methylation of L-arginine residues and is released into the cytoplasm after proteolysis. cSDMA is excreted by the kidneys and is a by-product of kidney metabolism. The level of SDMA in the blood can indicate the functional level of the kidneys. Generally, kidney function impairment can be detected as early as when 25% of kidney function is lost.

Clinical application:

• Early Nephropathy Screening:

Since cSDMA increases in the early stage of renal function impairment, it is a powerful tool for the early detection of chronic kidney disease. This helps to treat and manage dogs before symptoms appear and improve prognosis.

• Monitoring the Progression of Nephropathy:

By regularly determining the level of cSDMA, changes in renal function can be monitored, and the disease progression and treatment effect can be evaluated.

• Evaluating the Impact of Other Diseases on the Kidneys:

cSDMA can also be used to assess the impact of other systemic diseases (such as heart disease, hypertension, diabetes, etc.) on renal function.

• Guiding Treatment:

The cSDMA test results can assist veterinarians in formulating personalized treatment plans, including dietary adjustments, drug therapy, and lifestyle changes.